BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26089623)

  • 1. Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism.
    Suresh S; Vijayakumar T
    Indian J Clin Biochem; 2015 Jul; 30(3):345-50. PubMed ID: 26089623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
    J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HLA-G levels in women with polycystic ovary syndrome.
    Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
    Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism.
    Ibanez L; Potau N; Zampolli M; Prat N; Virdis R; Vicens-Calvet E; Carrascosa A
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1237-43. PubMed ID: 8772605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS.
    Li X; Yang D; Pan P; Azziz R; Yang D; Cheng Y; Zhao X
    Front Endocrinol (Lausanne); 2022; 13():873726. PubMed ID: 35769085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
    Enli Y; Fenkci SM; Fenkci V; Oztekin O
    Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome.
    Zhang H; Wang W; Zhao J; Jiao P; Zeng L; Zhang H; Zhao Y; Shi L; Hu H; Luo L; Fukuzawa I; Li D; Li R; Qiao J
    Front Endocrinol (Lausanne); 2022; 13():1085656. PubMed ID: 36699018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
    El-Eshmawy MM; Ibrahim A; Bahriz R; Shams-Eldin N; Mahsoub N
    BMC Endocr Disord; 2022 Dec; 22(1):315. PubMed ID: 36514085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome.
    Sharquie KE; Al-Bayatti AA; Al-Ajeel AI; Al-Bahar AJ; Al-Nuaimy AA
    Saudi Med J; 2007 Jul; 28(7):1039-43. PubMed ID: 17603706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain.
    Golbahar J; Al-Ayadhi M; Das NM; Gumaa K
    Int J Womens Health; 2012; 4():201-6. PubMed ID: 22654525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
    Sanke S; Chander R; Jain A; Garg T; Yadav P
    JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.
    Livadas S; Pappas C; Karachalios A; Marinakis E; Tolia N; Drakou M; Kaldrymides P; Panidis D; Diamanti-Kandarakis E
    Endocrine; 2014 Nov; 47(2):631-8. PubMed ID: 24752393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of luteinizing hormone vs follicular stimulating hormone ratio on anti-Müllerian hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].
    Li Y; Wei LN; Xiong YL; Liang XY
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):567-70. PubMed ID: 21029609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
    Allon MA; Leach RE; Dunbar J; Diamond MP
    Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.